Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has completed the acquisition of Apellis Pharmaceuticals, a pharmaceuticals business in Delaware, for $689 million. Biogen acquires Apellis Pharmaceuticals to add commercialized complement-driven therapies, including EMPAVELI and SYFOVRE, supporting growth in healthcare M&A. Apellis Pharmaceuticals also brings established nephrology commercial and medical infrastructure in DE acquisitions, helping Biogen accelerate launch readiness for felzartamab with a Phase 3 readout expected in 1H 2027. The merger acquisition is a strategic acquisition by a public biotech, with Biogen acquiring all outstanding shares for $41 per share in cash plus a contingent value right tied to SYFOVRE net sales thresholds.